DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...

The latest version of Abbott's FreeStyle Libre continuous glucose ... scanned of 'flash' CGM if it is available for the same or lower acquisition cost, according to the draft, which is due to ...

Abbott's ABT diversified business portfolio is well-positioned to drive momentum. However, the international business environment continues to be challenging globally. The stock carries a Zacks Rank ...

New research has examined how accurate continuous glucose monitors (CGM) are in comparison to capillary blood glucose measurements (CBGMs). The study has found that CGM can overestimate both fasting ...

DexCom said that on Tuesday it received a warning letter from the U.S. FDA following inspections at its facilities in San Diego, Calif., and Mesa, Ariz. related to concerns about manufacturing ...

The FDA cited issues with DexCom’s response to prior inspection findings, known as Form 483 observations. The inspections took place at the San Diego facility between October 21 and November 7, 2024, ...

Retatrutide is an new drug that has shown promise in the treatment of obesity and type 2 diabetes. Retatrutide is a type of multi-receptor agonist that targets multiple hormonal pathways involved in ...

When you refinance, you usually pay closing costs and fees. You won’t receive money from the loan unless you’re doing a cash-out refinance. Instead, your lender will use the loan amount to pay ...

Getting to know what’s going on in your body can help you manage type 2 diabetes well. It’s a chronic condition in which your body doesn’t use insulin properly. This causes sugar to build up ...